RE: cancer rates

From: Robert J. Bradbury (bradbury@aeiveos.com)
Date: Sun Sep 14 2003 - 14:55:57 MDT

  • Next message: Robert J. Bradbury: "Re: cancer rates"

    On Sun, 14 Sep 2003, Aubrey de Grey wrote:

    > All I have time to say right now is that there is a way out of the
    > "mess" that Robert describes, which is outlined at:
    >
    > http://www.gen.cam.ac.uk/sens/SENS3.htm

    Aubrey, my readings right now suggest that the ALT pathway for
    the extension of telomeres (or at least part of the ALT pathway)
    involves homologous recombination repair between telomeres. It
    makes sense since telomeres are essentially identical and so
    it is difficult to prevent short telomere from using a longer
    telomere as a repair substrate. If so it is going to be hard
    to deal with -- one has to suppress homologous recombination
    DNA repair in pre-cancerous cells. Not impossible mind you but
    pretty darn difficult. One would presumably turn down the
    ability to do homologous recombination repair system as the
    telomeres shorten. But I suspect there will be tissues where
    that has a significant negative impact (in terms of cell replacement
    capacity). One of the problems is that we don't fully understand
    the degree to which telomere extension needs to be tuned
    for specific tissues based on their cell division rate.
    I suspect the optimal balance between telomere extending
    and shortening is not attained in many tissues.

    So while I agree that there may be a partial path out of the "mess",
    I think we still have a lot more to learn.

    On a positive note, though I can't discuss it, Juvensa may be on
    the path towards a "homologous recombination-based gene therapy"
    approach that may be workable. If that plays out in a successful
    way you will have a much greater toolbox to work with.

    Robert



    This archive was generated by hypermail 2.1.5 : Sun Sep 14 2003 - 15:08:06 MDT